Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic, Pfizer Sign Deal for Alzheimer's Biomarker Discovery

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian biotech DiaGenic said it will use its gene expression technology to identify biomarkers of early-stage Alzheimer's disease for Pfizer, under a deal announced today by DiaGenic.

The firms will conduct a study, expected to begin this month, to compare longitudinal changes in blood-based gene expression patterns in patients with stable mild cognitive impairment, progressive MCI, and Alzheimer's disease. They hope to identify gene expression patterns in patients who progress from MCI to Alzheimer's disease and with different stages of the disease.

Pfizer will receive a non-exclusive, worldwide license for use of DiaGenic's MCI test and Alzheimer's test in its R&D development programs.

Additional terms of the deal were not disclosed.

In a statement, Erik Christensen, CEO of Oslo, Norway-based DiaGenic, said the deal "is the first result of DiaGenic's refocused strategy on teaming up with large pharmaceutical companies to deliver new diagnostic tools."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.